Real-world effectiveness of varicella vaccination in Guangzhou, China, 2017-2022: a matched case-control analysis.

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-24 DOI:10.1080/14760584.2025.2536086

Junxi Li, Yong Huang, Siyu Chen, Danyang Song, Yulan Chen, Yikun Chang, Jinwei Chen, Wangjian Zhang, Jun Yuan, Zhicheng Du

{"title":"Real-world effectiveness of varicella vaccination in Guangzhou, China, 2017-2022: a matched case-control analysis.","authors":"Junxi Li, Yong Huang, Siyu Chen, Danyang Song, Yulan Chen, Yikun Chang, Jinwei Chen, Wangjian Zhang, Jun Yuan, Zhicheng Du","doi":"10.1080/14760584.2025.2536086","DOIUrl":null,"url":null,"abstract":"Background: China has yet to implement a nationwide two-dose vaccination strategy. This study assesses the real-world effectiveness of varicella vaccination in Guangzhou, where the policy recommends voluntary, self-funded administration of two doses of the live attenuated vaccine, to provide insights for optimizing vaccination strategies.Research design and methods: Using outbreak data from 2017 to 2022 across preschools, primary, and secondary schools, we employed a three-level matched case-control design (school, grade, and class) and applied conditional logistic regression to estimate the effectiveness of single-dose (VE1) and two-dose (VE2) vaccinations, incremental VE, and the effectiveness of emergency vaccination.Results: From 2017 to 2022, 1,058 varicella cases were included in the study, with a median age of 9.0 years. The effectiveness of a single-dose vaccine ranged from 45.8% to 46.7%, while the two-dose vaccine showed higher effectiveness (94.5% to 95.8%), with an incremental VE of 89.7% to 92.1%. VE1 decreased over time, whereas VE2 remained relatively high within five years after the booster dose, with the interval between doses having little effect on VE2. Emergency vaccination was effective for the first dose (78.0%-84.5%) and more effective for the second dose (87.2%-91.4%).Conclusions: Single-dose varicella vaccination provides limited protection, whereas the two-dose regimen enhances effectiveness.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"601-611"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2536086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: China has yet to implement a nationwide two-dose vaccination strategy. This study assesses the real-world effectiveness of varicella vaccination in Guangzhou, where the policy recommends voluntary, self-funded administration of two doses of the live attenuated vaccine, to provide insights for optimizing vaccination strategies.

Research design and methods: Using outbreak data from 2017 to 2022 across preschools, primary, and secondary schools, we employed a three-level matched case-control design (school, grade, and class) and applied conditional logistic regression to estimate the effectiveness of single-dose (VE1) and two-dose (VE2) vaccinations, incremental VE, and the effectiveness of emergency vaccination.

Results: From 2017 to 2022, 1,058 varicella cases were included in the study, with a median age of 9.0 years. The effectiveness of a single-dose vaccine ranged from 45.8% to 46.7%, while the two-dose vaccine showed higher effectiveness (94.5% to 95.8%), with an incremental VE of 89.7% to 92.1%. VE1 decreased over time, whereas VE2 remained relatively high within five years after the booster dose, with the interval between doses having little effect on VE2. Emergency vaccination was effective for the first dose (78.0%-84.5%) and more effective for the second dose (87.2%-91.4%).

Conclusions: Single-dose varicella vaccination provides limited protection, whereas the two-dose regimen enhances effectiveness.

查看原文本刊更多论文

2017-2022年中国广州水痘疫苗接种的实际有效性：匹配病例对照分析

背景：中国尚未在全国范围内实施两剂疫苗接种战略。本研究评估了广州水痘疫苗接种的实际效果，该政策建议自愿、自费接种两剂减毒活疫苗，为优化疫苗接种策略提供见解。研究设计和方法：利用2017 - 2022年幼儿园、小学和中学的疫情数据，采用三水平匹配病例对照设计（学校、年级和班级），并应用条件logistic回归估计单剂（VE1）和双剂（VE2）疫苗接种、增量VE和紧急疫苗接种的有效性。结果：2017年至2022年，研究纳入了1058例水痘病例，中位年龄为9.0岁。单剂疫苗的有效性范围为45.8%至46.7%，而两剂疫苗的有效性更高（94.5%至95.8%），增量VE为89.7%至92.1%。VE1随着时间的推移而下降，而VE2在加强剂量后的五年内保持相对较高，两次剂量之间的间隔对VE2几乎没有影响。紧急预防接种第一剂有效（78.0% ~ 84.5%），第二剂有效（87.2% ~ 91.4%）。结论：单剂水痘疫苗提供有限的保护，而两剂方案可提高有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.